Looking into the future of presbyopia treatments

Article

During the American Academy of Optometry's Academy 2014, physicians and researchers peered into the future of treatments for presbyopia.

Denver-During the American Academy of Optometry's Academy 2014, physicians and researchers peered into the future of treatments for presbyopia.

Paul Kaufman, MD, professor and chair of ophthalmology and visual sciences, University of Wisconsin, Madison, reminded attendees that age causes functional declines in the machinery that drives accommodation, specifically the ability of the ciliary muscle to move and relax the zonular system.

3 correction options for presbyopes

“And if you're wondering why you don't get more than 2 D correction out of an accommodating intraocular lens, the answer is that your lenses aren't nearly good enough. You must be better than what Mother Nature designed. You've got to up your game significantly. But until you realize that, you're never going to play in that league – unless you find a biochemical or genetic way of changing the nature of connective tissue. We're a ways away from that."

Stephen D. McLeod, MD, professor and chair of ophthalmology, UCSF, says that surgically, "There are many different ways we could try to skin this cat. People are now thinking about not just the various materials and biocompatibility, but also, can we come up with some mechano-electric circuits so we can amplify the optical effect of the relatively small ciliary body function? Are there improved fluidics we can use to try to achieve curvature changes to give us the 5 to 10 D of change we need to get with very small muscle action?”

The only FDA-approved accommodating IOL works by shifting in the eye and in fact moving forward in response to an accommodation stimulus, says Susana Marcos, PhD, professor of research at the Instituto de Optica, Consejo Superior de Investigaciones Científicas, Madrid, Spain.  

Regardless of the approach, warned Dr. McLeod, “What we have to worry about when doing intraocular surgery is that we do have a fair amount of change in the biomechanics of the lens and capsular structures in the wound-healing process that follows cataract surgery,” which affects the therapeutic devices implanted. “So, lots of challenges lie ahead, but there are a lot of very bright people thinking about this. Hopefully in a few years-probably a few decades-we'll be doing a little better than bifocals and progressives.”

Newsletter

Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.

Recent Videos
Dr Luke Lindsell discusses retinal therapy and geographic atrophy at Controversies in Modern Eye Care 2025
Dr Neda Shamie speaks on cataract and refractive surgery at CIME 2025
Dr Selina McGee shares thoughts on pharmacological presbyopia correction at Controversies in Modern Eye Care 2025
Paul Hammond, OD, FAAO, presents a poster at ARVO 2025 on the creation of a conversion factor between 2 OCT devices to monitor glaucoma progression
What to know about legislative moves that have been made through May this year.
CIME 25: Dilsher Dhoot, MD, FASRS, is excited about emerging retinal therapies.
Robert Maloney, MD, MA, at the 2025 Controversies in Modern Eye Care meeting
Dr Jacob Lang at the 2025 Controversies in Modern Eye Care meeting
Steven Ferrucci, OD, FAAO, at Controversies in Modern Eyecare 2025
© 2025 MJH Life Sciences

All rights reserved.